At 12:00 PM in Alsh: Poster Discussion. #IMS26

Starting soon at #IMS26: Dr. Juan-Jose Garces will present a new method to identify patients with GPRC5D-negative multiple myeloma with t(11;14) translocation, helping guide clinical decision making.

🗓️ Friday, September 25
🕐 12 p.m. BT (7 a.m. ET)

@mskcancercenter.bsky.social

Abstract Sessions begin at 11:00 AM. Join us in Hall 5 for Abstract Session 7 or Lomond Auditorium for Abstract Session 8. #IMS26

In MIDAS trial, MRD-negativity rates improved after one-year isatuximab-iberdomide maintenance in MRD+ pts with newly diagnosed myeloma who had received single ASCT + Isa-KRd or tandem ASCT consolidation--- Aurore Perrot, MD, PhD #IMS26

At 10:00 AM in Hall 5: Riney Session. #IMS26

Jeffrey Zonder, MD, shared results from the first trial of Dara-Iber as post-transplant maintenance. Interim analysis of ongoing IBEX study shows improved IMWG response and MRD status with Dara-Iber maintenance. #IMS26

David Moreno, MD, PhD, shares GEM2014MAIN results. Pts with sustained MRD-neg at year 5 after 2-year len maintenance had prolonged PFS, compared to those who were MRD-neg at year 2 but converted to MRD+ at year 5. #IMS26

Dara maintenance reduced the need for subsequent therapy, and Dara-VTd induction/consolidation recipients achieved net survival approaching that of general population, according to CASSIOPEIA Registry analyses --- Jill Corre, PharmD, PhD #IMS26

Industry Symposium focuses on MoAs underlying rational treatment approaches that have demonstrated survival benefits across cytogenetic risk categories, age groups, fitness/frailty status, and disease settings. #IMS26

Read this Blood Cancer Discovery research brief by #IMS26 speakers Rahul Banerjee, Doris Hansen, and Surbhi Sidana, “Real-World Experience with Teclistamab for Relapsed/Refractory Multiple Myeloma from the US Myeloma Immunotherapy Consortium.” buff.ly/5TOvRE1 @rahulbanerjeemd.bsky.social

At 8:30 AM in Hall 5: Monitoring Immune System and Preventing Infections and Adverse Effects. #IMS26

Read this recent Blood Cancer Discovery spotlight by #IMS26 speaker Rahul Banerjee, “Sequenced, Not Stirred: Positioning CAR T and Bispecific Antibody Therapy in Multiple Myeloma.” buff.ly/pnAnzRr @rahulbanerjeemd.bsky.social

Welcome to Day 3 of #IMS26. Join us for breakfast at 7:15 AM in Hall 5 during the Industry Symposium Supported by Gilead and Kite Oncology (not intended for HCPs from the UK), then take part in another day of scientific exchange and discussion. View the program: ow.ly/hi6650ZQtxs

Read the recently updated Myeloma Collection, showcasing impactful articles published in Blood Cancer Discovery: buff.ly/CnLyN2M #IMS26

Another inspiring day in Glasgow. From groundbreaking science to meaningful conversations, here’s a look at Day 2 of #IMS26.

Day 2 highlights from the 23rd IMS Annual Meeting! #IMS26

#CCTG MY13 study gets a shout out from the podium at #IMS26 during the session on optimal maintenance by Dr Pawlyn as a study asking key questions about current standards of care. @myelomasociety.org

Adrián Mosquera Orgueira, MD, PhD, explains governance principles that can help deploy clinical AI in real-world practice, during the IMS/EHA joint session. #IMS26

At the IMS/EHA joint session, Peter Valk, PhD, spoke about the molecular analyses that helped make sense of the heterogeneity of AML and enabled the discovery of therapeutic targets. #IMS26

During the IMS/AACR joint session, Robert Jenq, MD, spoke about the impact of commensal gut bacteria on immune modulation in the context of cancer immunotherapies, including CAR-Ts & bispecifics, & potential mechanisms. #IMS26